Progenics Pharma (NASDAQ: PGNX) is ramping 21% in pre-open trade Wednesday after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Momentum Movers Trader Talk

Brean Capital Sees 'Significant Uptake' for Progenics' (PGNX) Oral RelistorJuly 20, 2016 10:22 AM Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & CompanyJuly 20, 2016 9:16 AM BTIG Positive on Progenics Pharma (PGNX) Following FDA Approval of RELISTOR as OIC Treatment (VRX)July 20, 2016 7:57 AM Progenics (PGNX) volatility elevated into FDA approval of constipation treatment July 20, 2016 5:43 AM Valeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTORJuly 19, 2016 6:06 PM Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer PainJuly 19, 2016 6:04 PM